Roytman, Marina
Ramkissoon, Resham
Wu, Christina
Hong, Leena
Trujillo, Ruby
Huddleston, Leslie
Poerzgen, Peter
Seto, Todd
Wong, Linda
Tsai, Naoky
Article History
Received: 11 November 2015
Accepted: 28 February 2016
First Online: 30 March 2016
Compliance with ethical standards
:
: None.
: Naoky Tsai has received research grants, unrelated to this research project, from the following companies; AbbVie, Janssen, Gilead Sciences, BMS and Beckman Coulter. Naoky Tsai is on the advisory board of Gilead Sciences and AbbVie. Naoky Tsai is part of the speaker’s bureau for AbbVie, Janssen, Gilead Sciences, BMS, Salix and Bayer Healthcare. Marina Roytman is on the speaker’s bureau and advisory board for Gilead and Sciences. Linda Wong is on the speaker’s bureau for Gilead Sciences. All other authors have no conflicts of interest to declare.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Queen’s Medical Center Research and Institutional Review Committee (approval #RA-2014-048) as well as with the 1964 Helsinki Declaration and its later amendments. This article does not contain any studies with animals performed by any of the authors.
: A waiver for informed consent was obtained by the Queens Medical Center Institutional Review Committee (approval #RA-2014-048). This study fulfilled the following criteria: (1) an observational study that involved no more than minimal risk to subjects, (2) a waiver of informed consent did not adversely affect subjects’ right and welfare, (3) the research could not practicably be conducted without the waiver, and (4) the patient received all pertinent information during office visits as they are followed at the Queen’s Liver Center.
Free to read: This content has been made available to all.